Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 6, November-December, p. 1139–1147

doi: 10.17219/acem/63752

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Glycogen Synthase Kinase-3β (GSK-3β) and Nuclear Factor Kappa-B (NFKB) in Childhood Acute Lymphoblastic Leukemia

Cristian Fabian Layton Tovar1,A,B,C,D, Hugo Mendieta Zerón2,A,C,D,E,F, Maria Del Socorro Camarillo Romero3,A,E, Yanko V. Fabila Sánchez4,A,C,E, Isidoro Tejocote Romero5,B,E

1 School of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico

2 Latin American Scientific Association and Ciprés Medical Group, Toluca, Mexico

3 Medical Sciences Research Center, Autonomous University of the State of Mexico, Toluca, Mexico

4 Terranova University, Toluca, México

5 Hematology and Oncology Service, The Children’s Hospital, Maternal Child of the State of Mexico Institute, Toluca, Mexico


Background. Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy in early childhood. In children with acute lymphoblastic leukemia (ALL), the activity of glycogen synthase kinase (GSK-3β) has been associated with changes in the transcriptional activity and expression of nuclear factor kappa beta (NFKB) in the mononuclear cells of bone marrow.
Objectives. The aim of the study was to determine the possible role of glycogen synthase kinase 3beta (GSK-3β) and nuclear factor kappa beta (NFKB) as prognostic variables in pediatric patients with ALL.
Material and Methods. This was a descriptive, transversal, and observational study. Bone marrow and blood samples were obtained from 30 children with newly-diagnosed ALL, who were seen at the Hematology-Oncology Service, Hospital para el Niño (HPN), Toluca, Mexico, from 2014‒2015. Anthropometric variables, clinical lab results, immunophenotype and cytogenetic abnormalities were registered. GSK-3β was evaluated through immunohistochemistry, and NFKB messenger RNA (mRNA) with real-time polymerase chain reaction (qPCR). The cases of ALL were classified into two groups of risk: high and habitual.
Results. Thirty patients were included in this study, with a mean age of 7.1 years (range 2‒13 years). Twenty-one were male and 9 female. Employing the morphological classification, 26 patients had type L1 ALL and the remaining 4 patients had type L2 ALL. Abnormal genes were found in 7 (23.33%) patients, ETV-RUNX1 in 3, followed by TCF3-PBX1 (two), STL1-TAL1 (one), and BCR-ABL1 (one). NFKB relative expression levels, in comparison to the GSK-3β immunohistochemistry results of the bone marrow samples, showed significant differences between positive and negative cases (p = 0.001) and between weak-positive and negative cases (p = 0.002).
Conclusion. These results suggest that GSK-3β may be a prognostic biomarker in childhood ALL.

Key words

acute lymphoblastic leukemia, GSK-3β, NFKB, prognostic

References (23)

  1. Winter SS: Pediatric acute leukemia therapies informed by molecular analysis of high-risk disease. Hematology/ the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011, 2011, 366–373.
  2. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G: Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004, 104, 3679–3687.
  3. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro, RC: Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002, 100, 52–58.
  4. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008, 111, 5477–5485.
  5. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322, 1377–1380.
  6. Pui CH, Pei D, Sandlund JT: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24, 371–382.
  7. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) Method. Methods 2001, 25, 402–408.
  8. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115, 5393–5397.
  9. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A: Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet 2008, 372, 1484–1492.
  10. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK: Targeting paediatric acute lymphoblastic leukaemia: Novel therapies currently in development. Br J Haematol 2010, 151, 295–311.
  11. Safa M, Tavasoli B, Manafi R, Kiani F, Kashiri M, Ebrahimi S: Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells. Tumour Biol 2015, 36, 3919–3930.
  12. Poglio S, Cahu X, Uzan B, Besnard-Guérin C, Lapillonne H, Leblanc T: Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF-κB pathway activation but not with poor prognosis. Leukemia 2015, 29, 977–980.
  13. Hu Y, Gu X, Li R, Luo Q, Xu Y: Glycogen synthase kinase-3 beta inhibition induces nuclear factor kappa B mediated apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin Cancer Res 2010, 29, 154.
  14. Zhang H, Zhu L, He H, Zhu S, Zhang W, Liu X: NF-kappa B mediated up-regulation of CCCTC-binding factor in pediatric acute lymphoblastic leukemia. Mol Cancer 2014, 7, 13–15.
  15. Ding VW, Chen RH, McCormick F: Differential regulation of glycogen synthase kinase 3 beta by insulin and Wnt signaling. J Biol Chem 2010, 275, 32475–32481.
  16. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO: Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 2011, 108, 1204–1213.
  17. Gould TD, Quiroz, JA, Singh J, Zarate CA, Manji HK: Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Molecular Psychiatry 2004, 9, 734–755.
  18. Jope RS, Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29, 95–102.
  19. Kuzhuvelil BH, Ajaikumar BK, Kwang SA, Preetha A, Sunil K, Sushovan G, Bharat BA: Modification of the cysteine residues in Ikappa B alpha kinase and NF-kappa B (p65) by xanthohumol leads to suppression of NF kappa B-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 2009, 113, 2003–2013.
  20. Huang WC, Lin YS, Chen CL, Wang CY, Chiu WH, Lin CF: Glycogen synthase kinase-3 beta mediates endoplasmic reticulum stress-induced lysosomal apoptosis inleukemia. J Pharmacol Exp Ther 2009, 329, 524–531.
  21. Hsieh MY, Van Etten RA: IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood 2014, 123, 2401–2411.
  22. Wang XJ, Xu YH, Yang GC, Chen HX, Zhang P: Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3β. Oncol Rep 2015, 33, 2368–2374.
  23. Pacheco C, Lucchini G, Valsecchi MG, Malta A, Conter V, Flores A, Biondi A, Tognoni G, Arguello M, Cavalli F, Silvestri D, Lacayo FB, Masera G: Childhood acute lymphoblastic leukemia in Nicaragua: Long-term results in the context of an international cooperative program. Pediatr Blood Cancer 2014, 61, 827–832.